Kure It Medical Advisory Board

CLINICAL PROFESSOR, DEPARTMENT OF MEDICAL ONCOLOGY & THERAPEUTICS RESEARCH, CO-DIRECTOR, KIDNEY CANCER PROGRAM | CITY OF HOPE Sumanta (Monty) Kumar Pal, M.D., is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope‘s Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution. Dr. Pal entered college at the age of 13 and began medical school at University of California, Los Angeles at the age of 17. After completing his residency training at University of California, Los Angeles, Dr. Pal completed a fellowship program in medical oncology at City of Hope’s Comprehensive Cancer Center where he remains on faculty since 2009. Over that span of time, he has published more than 200 peer-reviewed articles that have been featured in prominent journals including The Journal of Clinical Oncology, Lancet Oncology, Cancer Cell, and European Urology. He has worked to push the boundaries of personalized medicine in genitourinary cancers, with several seminal publications in rare genitourinary cancers that describe unique therapeutic targets. Dr. Pal was an early Kure It Grant Recipient and supporter. He currently sits on our Board of Directors and is Chairman of Kure It’s Medical Advisory Board.

PROFESSOR OF MEDICINE, HUNTSMAN CANCER INSTITUTE (HCI ) PRESIDENTIAL ENDOWED CHAIR OF CANCER RESEARCH CO-LEADER, HCI EXPERIMENTAL THERAPEUTICS PROGRAM (CCSG PROGRAM), DIRECTOR, CENTER OF INVESTIGATIONAL THERAPEUTICS, DIRECTOR, GENITOURINARY ONCOLOGY PROGRAM Neeraj Agarwal, MD, is the Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research, and the Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. He also directs the Center of Investigational Therapeutics and co-leads the “Experimental Therapeutic Program” at the Huntsman Cancer Institute. Dr. Agarwal has authored more than 200 peer-reviewed articles and book chapters. He serves as a panel member for the NCCN guideline-committees for bladder and kidney cancer. Dr. Agarwal also serves as the overall study chair and/or steering committee member of multiple national and international clinical trials in GU cancers. Dr. Agarwal has the prestigious honor of being chosen as one of the five young investigators of the Southwest Oncology Group in 2009, was appointed as the leader of early therapeutics of the SWOG Genitourinary Cancer Scientific leadership Committee in 2010, received the 2009-2010 William D. Odell Young Investigator award, and received the 2014 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI).

DIRECTOR, LANK CENTER FOR GENITOURINARY ONCOLOGY, DEPARTMENT OF MEDICAL ONCOLOGY, DANA-FARBER CANCER INSTITUTE, CO-LEADER, KIDNEY CANCER PROGRAM, DANA-FARBER/HARVARD CANCER CENTER, THE JEROME AND NANCY, KOHLBERG PROFESSOR OF MEDICINE, HARVARD MEDICAL SCHOOL Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI)/Brigham and Women’s Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and past President of the Medical Staff at Dana-Farber (2016-2018). He is the recipient of the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI and the Eugene P. Schonfeld Award from the KCA. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, the GU Steering Committee (GUSC) Task Force of the National Cancer Institute (NCI), and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the Kidney Cancer Association (KCA). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania. Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including Kidney Cancer. His research also focuses on the epidemiology, diagnosis and treatment outcomes of GU cancers using large scale approaches such as meta-analyses from available published trials or national databases. He has been funded by the NCI, the Department of Defense (DOD), the American Society of Clinical Oncology (ASCO), the Harvard Kidney Cancer SPORE, and Industry partners. His work has been published in journals such as the New England Journal of Medicine, Nature, Science, Cancer Cell, Journal of American Medical Association, Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research, and many others. He lectures frequently throughout the United States and around the world. He has over 500 PubMed-listed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers.